Short answer
Nuvation Bio Inc. (NUVB) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.
Nuvation Bio Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full operating metrics and financial details contained in Exhibit 99.1
- Information furnished under Item 2.02, limiting its use in Section 18 liability and incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $31.7M, including $23.2M IBTROZI product sales, signaling accelerating commercial adoption
- IBTROZI sales grew 25% QoQ, with approximately 85% of 160 new starts TKI-naïve
- Net loss widened to $62.8M, or $0.18 per share, despite operating loss improving to $51.0M
- Cash, equivalents, and marketable securities totaled $661.0M, supplemented by $36.5M July note overallotment proceeds
- Safusidenib Phase 2 showed 51.9% ORR and 79.1% 36-month PFS, supporting expanded Phase 3 and post-vorasidenib development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvation Bio Inc. 8-K filings
Get the next NUVB 8-K as it lands
Follow NUVB for push alerts, or ask the research agent what this filing means.